AAP (Anti Appetite Peptide) – 3MG per vial

R 1050,00 Excl. VAT

Aids type 2 diabetis. Assist with large scale weight loss.

Category: Tags: , , Product ID: 2877

Description

Clinical Test Expectation – AAP (Anti Appetite Peptide) – 3MG – Human Subjects : Aids type 2 diabetis. Assist with large scale weight loss.
Strength – 3MG per vial

Formulation under patent review : Contains Natural Semaglutide, Pyy3-36 peptide and JBSNF-000088 peptide.

Introduction

YY3-36 Peptide YY reduces gastric emptying, and slows intestinal transit time. This effect is termed the “ileal brake” as it represents the ability of the distal small intestine (Ileum) to inhibit gastric emptying. This slowing of intestinal transit is reproduced by infusion of PYY(3-36) to healthy volunteers. Peptide YY (PYY) 3-36 is one of the two main endogenous forms of PYY, a hormone released in endocrine cells in the human small intestine after a meal. Infusion of PYY 3-36 has been reported to reduce hunger and food intake in obese volunteers – https://www.sciencedirect.com/topics/medicine-and-dentistry/peptide-yy-3-36

JBSNF-000088 Reduces body weight and restores glucose tolerance in patients with diet-induced obesity (DIO). Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that catalyzes the transfer of a methyl group from the co-factor S-adenosyl-L-methionine (SAM) onto the substrate, nicotinamide (NA) to form 1-methyl-nicotinamide (MNA). Higher NNMT expression and MNA concentrations have been associated with obesity and type-2 diabetes. Here we report a small molecule analog of NA, JBSNF-000088, that inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease. In mice with high fat diet (HFD)-induced obesity, JBSNF-000088 treatment caused a reduction in body weight, improved insulin sensitivity and normalized glucose tolerance to the level of lean control mice. These effects were not seen in NNMT knockout mice on HFD, confirming specificity of JBSNF-000088. The compound also improved glucose handling in ob/ob and db/db mice albeit to a lesser extent and in the absence of weight loss. Co-crystal structure analysis revealed the presence of the N-methylated product of JBSNF-000088 bound to the NNMT protein. The N-methylated product was also detected in the plasma of mice treated with JBSNF-000088. Hence, JBSNF-000088 may act as a slow-turnover substrate analog, driving the observed metabolic benefits. – https://pubmed.ncbi.nlm.nih.gov/29483571/

Natural Semaglutide derivative (under patent review) – Mechanism of action –
Historically, the treatment of obesity focused almost exclusively on lifestyle-based approaches. However, evidence that diet and exercise prompt physiological counterregulatory mechanisms that limit weight reduction and impede weight maintenance has led to the realization that obesity is a complex, multicomponent metabolic disease of energy homeostasis involving central and peripheral mechanisms. Once obesity is present, those mechanisms render a return to lower weight difficult. Accordingly, several clinical guidelines now recommend treatment with antiobesity medications for people with obesity or for those with overweight and weight-related complications. Recent studies with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists demonstrated that greater efficacy with acceptable safety could be achieved by targeting the pathways of endogenous nutrient-stimulated hormones. Glucose-dependent insulinotropic polypeptide (GIP), another nutrient-stimulated hormone, regulates energy balance through cell-surface receptor signaling in the brain and adipose tissue. A molecule that combines both GIP and GLP receptor agonism theoretically may lead to greater efficacy in weight reduction.

AAP is a once-weekly subcutaneous injectable peptide (for type 2 diabetes) engineered using the a unique (under patent review) GIP sequence, with agonist activity at both the GIP and GLP-1 receptors. Preclinical data demonstrated that the affinity of our *under patent formula* for GIP receptors was equal to the affinity of natural GIP for GIP receptors, whereas AAP binds GLP-1 receptors with affinity approximately five times weaker than native GLP-1 bound GLP-1 receptors. GIP activation appeared to act synergistically with GLP-1 receptor activation to allow greater weight reduction in humans than that achieved with GLP-1 receptor monoagonism. In phase 2 studies in people with type 2 diabetes, our product induced clinically relevant weight reduction, warranting further investigation for the treatment of obesity. The recent reviews on this item have proven the efficacy and safety of this item in obese adults or overweight adults who did not have diabetes with great success

Dosing Details – AAP (Anti Appetite Peptide) – 3MG
You inject 1ml water into the vial of AAP – 2MG from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in colour you draw out the entire vial and inject it into the tummy under the skin into the fatty skin layer.

How long will a vial last ?
A vial should last 7 days.
Tirzepatide
Whatsapp our support team now for help with this item or others ! Click HERE to connect with us !

Additional information

Weight 1 g
Dimensions 4 × 1,5 × 4 cm

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.